View Older Stories
-
BMO Capital Reiterates Outperform Rating on Merck (MRK), but Awaits "More Concrete Data" on Cardiovascular Programs
-
BMO Capital Reiterates Market Perform Rating on Merck (MRK) Following Earnings
-
BMO Capital Starts Merck (MRK) at Market Perform
-
Merck (MRK) PT Raised to $84 at BMO Capital
-
Merck (MRK) PT Raised to $83 At BMO On Keytruda Market Opportunity
-
BMO Capital Downgrades Merck (MRK) to Market Perform
-
Merck (MRK) PT Lowered to $80 at BMO Capital
-
Merck (MRK) PT Raised to $82 at BMO Capital
-
Dr. Roger Dansey Departure at Merck (MRK) an 'Incrementally Negative' - BMO
-
Merck (MRK) PT Raised to $70 at BMO Capital
-
Merck's Keytruda helps lung cancer patients live longer in trial
-
ECHO-301 Not a Key Driver for Merck (MRK) - BMO
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $51 at BMO Capital; 'IO NSCLC Complexity Increases'
-
AbbVie (ABBV), Eli Lilly (LLY) More Vulnerable Than Other Drug Cos. on Amazon Entry - BMO
-
Merck (MRK) PT Raised to $72 at BMO Capital
-
Merck (MRK) Surges as it May Have Made Chemo Alone Obsolete in First-Line Treatment for Non-Small Cell Lung Cancer
-
Merck (MRK) Defended at BMO Capital
-
Merck (MRK) PT Lowered to $73 at BMO Capital Ahead of 2Q Announcement on 7/28 BMO; '2Q Should be In-Line'
-
Merck (MRK): ASCO Data Increases Confidence in LT Story - BMO
-
Merck (MRK) PT Raised to $74 at BMO Capital; Keytruda 1L-Lung Approval a 'Meaningful Positive'
-
Merck (MRK): Expecting a Miss - BMO
-
Merck (MRK) PT Lowered to $70 at BMO Capital on EPOCH Stoppage
-
Merck (MRK): Expecting Guidance Downside, Cutting PT - BMO
-
AstraZeneca (AZN) MYSTIC Change Positive for Merck (MRK), Less so for Bristol-Myers Squibb (BMY) - BMO
-
Complete Donald Trump Stock Impact Guide
-
Major Pharma Got a Major Win Last Night - BMO
-
Pre-Open Stock Movers 10/10: (IPCI) (TSRO) (MYL) Higher; (TWTR) (BMY) (DOV) Lower (more...)
-
BMO Capital Upgrades Merck (MRK) to Outperform, $72 PT
-
Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)
-
Merck (MRK): Good But Not Enough - BMO
-
BMO Capital Downgrades Merck (MRK) to Market Perform
-
Merck (MRK): Management Meeting Reinforced Bullish Views - BMO
-
Could Merck (MRK) Join the Bidding for Medivation (MDVN)?
-
Latest Data from EASL Shows Gilead (GILD) Continues to Dominate Hep-C Market - BMO Capital
-
BMO Capital Cuts Price Target on Merck (MRK) Following FDA's Zepatier Approval
-
Bristol-Myers (BMY) JP Morgan Update 'Incrementally Positive', Negative for Merck (MRK) - BMO Capital
-
BMO Incrementally More Positive on Merck (MRK) as Omarigliptin Met Primary Endpoint in Phase 3
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
Notable Analyst Rating Changes 05/08: (SCTY) (YELP) (FOSL) Upgraded; (MRK) (AGN) (PENN) Downgraded
-
BMO Capital Downgrades Merck (MRK) to Market Perform
-
Notable Analyst Rating Changes 05/07: (JCP) (ABBY) (FE) Upgraded; (WFM) (GNC) (GRPN) Downgraded
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
Notable Analyst Rating Changes 07/18: (EXC) (LNC) (XLNX) Upgraded; (NTRS) (TLM) (MRK) Downgraded
-
BMO Capital Downgrades Merck (MRK) to Market Perform
-
Notable Analyst Rating Changes 05/28: (GSK) (KSU) (MRK) Upgraded; (STJ) (FE) (VSAT) Downgraded
-
BMO Capital Upgrades Merck (MRK) to Outperform
-
BMO Capital Starts Merck (MRK) at Outperform
-
BMO Cuts Cardiome Pharma (CRME) to Market Perform Amid Vernakalant News
-
David Moenning's Daily State of the Markets: 7/21
-
David Moenning's Daily State of the Markets: 3/13